MI Profile for U.S. (excluding New York)
MI Profile is a multi-platform, solid tumor biomarker analysis for therapeutic decision support and clinical trials matching. Technologies used to assess DNA, RNA and Proteins include, Next-Generation Sequencing DNA/RNA (also called MI Tumor Seek), Pyro Sequencing, Fragment Analysis, Immunohistochemistry and Chromogenic in situ Hybridization.
The information below details the biomarkers tested and technology platforms utilized by tumor type.
View the full MI Profile Menu for U.S. here: Profile Menu Brochure
In certain instances, some biomarkers included in MI Profile or genes ordered individually will not associate with commercially available cancer therapies or clinical trials.
For PD-L1 IHC testing, Dako antibody 22c3 or antibody SP-142 are available upon request.
For certain patients, HER2 testing is performed by Chromogenic in situ Hybridization, in addition to Next-Generation Sequencing.
For certain patients, MSI testing is performed by Fragment Analysis.
For all cases with an MSI result of equivocal, MMR IHCs (MLH1, MSH2, MSH6, PMS2) will be performed.
The following TAPUR NGS genes are available upon request: EPHA2, FYN, GLI2, LYN, POLD1, MST1R, YES1, and NGS Fusion: Bcrl-abl.